Moving forward
MVT has developed a new, patented formulation, MVT-100, for use as an ultrasound contrast agent, which has completed Phase II clinical trials.
MVT-100 has a neutral surface chemistry, potentially serving as a platform for development of agents for molecular imaging and image-guided therapy. We've received formal guidance from the FDA that MVT-100 is regulated via the 505(b)(1) pathway.
Momentum with MVT–100
PHASE II Complete
MVT–100
Indication:
Echocardiography
505(b)(1) Regulatory Pathway — Patent granted for improved microbubble formulation.
PRE-CLINICAL
MVT–101
Indication:
Ultrasound Mediated Tumor Ablation with Phase Shift Microbubble (PSMB) - Brain Cancer
Nanobubbles are used in combination with Magnetic Resonance Guided Focused Ultrasound (MRgFUS) to perform non-thermal brain tumor ablation. Research is in partnership with the University of Utah and funded by the National Cancer Institute,
• ISSUED PATENT
MVT–201
Indication:
Sonothrombolysis - Myocardial Microvascular Obstruction (MVO), Stroke, Deep Vein Thrombosis and Pulminary Embolism
Thrombin-targeted nanobubbles supported by $4MM Department of Defense Grant.
MVT has right of reference to data showing efficacy of microbubble enhance sonothrombolysis using perflutren. MVT has exclusive right to condensed Phase Shift Microbubbles (PSMB).
• ISSUED PATENT
MVT–301
Indication:
Alzheimer's Disease
Dissolution of amyloid plaques in Alzheimer's using proprietary nanobubbles and ultrasound.
• ISSUED PATENT
• PATENT PENDING
MVT–401
Indication:
Pancreatic Cancer
Detection of pancreatic cancers <1MM in size.
• ISSUED PATENT
• IN-LICENCE
MVT–501
Indication:
Breast Cancer
Improved detection and differentiation on routine breast ultrasound, enabling faster, more accurate, and cheaper detection and treatment of breast cancer.
• ISSUED PATENT
MVT–601
Indication:
Uveitis
E-selection targeted microbubble for the diagnosis of uveitis. Potential for drug delivery and treatment of macular degeneration.
• ISSUED PATENT
• PATENT PENDING
